IRIS
IZZO, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.714
EU - Europa 2.664
AS - Asia 2.653
SA - Sud America 917
Continente sconosciuto - Info sul continente non disponibili 225
AF - Africa 78
OC - Oceania 4
Totale 9.255
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.455
SG - Singapore 1.210
IT - Italia 969
RU - Federazione Russa 846
BR - Brasile 678
VN - Vietnam 486
CN - Cina 476
HK - Hong Kong 174
MX - Messico 160
DE - Germania 151
UA - Ucraina 142
FR - Francia 116
NL - Olanda 116
FI - Finlandia 86
GB - Regno Unito 67
CA - Canada 64
CO - Colombia 63
IN - India 56
JP - Giappone 56
EC - Ecuador 47
BD - Bangladesh 42
IE - Irlanda 39
AR - Argentina 38
ES - Italia 32
KR - Corea 28
PE - Perù 28
BO - Bolivia 25
ZA - Sudafrica 25
IQ - Iraq 21
PH - Filippine 20
CL - Cile 19
CI - Costa d'Avorio 18
SE - Svezia 18
PL - Polonia 13
AT - Austria 12
PK - Pakistan 12
TH - Thailandia 11
CH - Svizzera 10
ID - Indonesia 10
TR - Turchia 10
VE - Venezuela 10
HN - Honduras 7
ET - Etiopia 6
MY - Malesia 6
CR - Costa Rica 5
HR - Croazia 5
KE - Kenya 5
LV - Lettonia 5
PT - Portogallo 5
PY - Paraguay 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
AL - Albania 4
BE - Belgio 4
BG - Bulgaria 4
DO - Repubblica Dominicana 4
JM - Giamaica 4
MA - Marocco 4
SC - Seychelles 4
TW - Taiwan 4
EG - Egitto 3
GE - Georgia 3
IR - Iran 3
JO - Giordania 3
LT - Lituania 3
NI - Nicaragua 3
RO - Romania 3
SN - Senegal 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BW - Botswana 2
CU - Cuba 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GA - Gabon 2
GT - Guatemala 2
LB - Libano 2
LU - Lussemburgo 2
ML - Mali 2
PA - Panama 2
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
BZ - Belize 1
CV - Capo Verde 1
DM - Dominica 1
EE - Estonia 1
GF - Guiana Francese 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LY - Libia 1
MK - Macedonia 1
NC - Nuova Caledonia 1
Totale 9.020
Salva come PNG Salva come JPEG
Città #
Singapore 548
San Jose 386
Moscow 229
Ashburn 212
Chandler 176
Hong Kong 171
Beijing 158
Ho Chi Minh City 130
Naples 112
Amsterdam 103
Hanoi 99
Hefei 91
Napoli 80
Los Angeles 77
The Dalles 77
Santa Clara 71
Jacksonville 69
Lauterbourg 56
Rome 56
Millbury 52
Munich 51
Tokyo 50
São Paulo 45
Princeton 44
Milan 43
New York 40
Boston 37
Buffalo 31
Nanjing 28
Da Nang 25
Turku 25
Des Moines 24
Ottawa 24
Lima 23
Quito 23
Frankfurt am Main 21
Medellín 21
Mexico 21
Redondo Beach 21
Council Bluffs 20
Haiphong 20
Woodbridge 20
Brasília 19
Wilmington 18
Brooklyn 17
Chennai 17
La Paz 17
Seoul 17
Bogotá 16
Dallas 16
Poplar 16
Seattle 16
Santiago 15
Denver 14
Helsinki 14
Orem 14
Chicago 13
Montreal 13
Warsaw 13
Bari 12
Dong Ket 12
Houston 12
Shenyang 12
Toronto 12
Cuenca 11
Falls Church 11
Johannesburg 11
Nuremberg 11
Salvador 11
Caserta 10
Lawrence 10
London 10
Mexico City 10
Salerno 10
Fortaleza 9
Atlanta 8
Belo Horizonte 8
Buenos Aires 8
Hebei 8
Nanchang 8
Turin 8
Biên Hòa 7
Can Tho 7
Florence 7
Genova 7
Manaus 7
Mumbai 7
New Delhi 7
Ninh Bình 7
Rio de Janeiro 7
San Francisco 7
Tijuana 7
Vienna 7
Bologna 6
Brescia 6
Charlotte 6
Kronberg 6
Madrid 6
Monterrey 6
Palmi 6
Totale 4.223
Salva come PNG Salva come JPEG
Nome #
Leucemia Mieloide Cronica 1.429
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 441
NANOG: ITS ROLE IN THE TKI RESISTANCE OBSERVED IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA 217
Laboratory medicine: health evaluation in elite athletes 195
Transition index: new original tool to identify subsets overlapping MPN phenotypes. 178
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 171
A Novel Score to Predict Interferon-Alpha Therapy Responsiveness in Patients with Essential Thrombocythemia 168
Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation 168
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 162
Spleen is the dark side of essential Thrombocitemia 159
RISPOSTA EMATOLOGICA AL TRATTAMENTO CON LENALIDOMIDE IN UNA PAZIENTE AFFETTA DA TROMBOCITEMIA ESSENZIALE JAK2 V617F-POSITIVA E SINDROME MIELODISPLASTICA ASSOCIATA A DEL(5Q) 157
MOLECULAR EVALUATION OF ZNF224 MRNA EXPRESSION IN CML PATIENTS AS A NOVEL DETERMINANT OF TKI RESPONSIVENESS 154
Identification of SARS-CoV-2 Proteins from Nasopharyngeal Swabs Probed by Multiple Reaction Monitoring Tandem Mass Spectrometry 152
SPLEEN VOLUME IS THE MOST ACCURATE PARAMETER TO AVOID UNDERSTIMATION OF 25% SPLENOMEGALIC PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA 149
FLUORESCENT IN SITU HYBRIDIZATION (FISH) ON PERIPHERAL BLOOD AND BONE MARROW SMARS: 120 MINUTES FOR DETECTION OF PML/RARa FUSION GENE 144
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 143
SARS-CoV-2 Subgenomic N (sgN) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, as Evaluated by Five Different Molecular Methods 142
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia. 138
CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL 136
Molecular Analysis of Cluster Headache 135
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition 133
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate 132
Coesistence of two distinct cell populations (CD56+Tcr gammadelta+ and CD56+ Tcr gammadelta-) in a case of aggressive CD56+ lymphoma/leukemia 131
Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-),derived from a single patient with CD56+ non- Hodgkin's lymphoma. 128
MiR‐27a downregulates 14‐3‐3θ, RUNX1, AF4, and MLL‐AF4, crucial drivers of blast transformation in t(4;11) leukemia cells 126
A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR 126
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia 125
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. 125
Coexistence of two distinct cell populations (CD56+TcRgd+ and CD56+TcRgd-) in a case of aggressive CD56+ lymphoma/leukemia 124
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical relation. 124
Bone marrow mesenchymal stem cells as a possible ruxolitinib reservoir in the bone marrow niche 117
Molecular monitoring in chronic myeloid leukemia (CML) 117
Decitabine up-regulates the expression of the cancer-associate prame antigen in early chronic phase CML cells. 116
c-Kit M541L variant is related to ineffective hemopoiesis predisposing to clonal evolution in 3D in vitro biomimetic co-culture model of bone marrow niche 115
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 115
Molecular analysis of T-cell Acute Lymphoblastic Leukemia arising after Essential Thrombocythemia foreshadows a distinct clonal route for lymphoid blast crisis in Philadelphia-negative chronic myeloproliferative neoplasm: a case report with literary review 113
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 111
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia 110
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. 108
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 106
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 106
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study 105
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. 105
Droplet digital pcr for bcr–abl1 monitoring in diagnostic routine: Ready to start? 102
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study 101
Early detection of residual disease by Q-RT-PCR of the hybrid BCR/ABL transcript is a powerful predictor of treatment response in adult Philadelphia - Positive acute lymphoblastic leukemia. 99
CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL 98
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in any high complete molecular response. 93
Wt1 expression levels combined with flow cytometry blast counts for risk stratification of acute myeloid leukemia and myelodysplastic syndromes 89
THE AUTOMATED MOLECULAR TECHNIQUE “ULTRA” ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 87
Defining low and undetectable levels of disease in chronic myeloid leukemia:progress towards standardisation in Europe 85
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network 81
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. 81
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent 80
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database 78
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. 78
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. 78
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia 75
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale 73
A novel MLL/AF4 fusion gene lacking the AF4 transactivating domain in infant acute lymphoblastic leukemia. 70
Late appearance of t(8;14) with c-myc rearrangement and disappearance of JH rearrangement leading to aggressive progression in a case of low grade non Hodgkin’s lymphoma” 69
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy 68
Presence of FLT3 Mutations Does Not Impair Stem Cell Mobilization and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia 57
Novel multiplex droplet digital pcr assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical bcr-abl1 transcripts 47
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype 44
Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches 37
CV1 Chimpanzee Adenovirus Efficiently Transduces Mesenchymal Stem and Leukemia Cells: Implications for Cellular Targeting and Vector Tropism 29
Totale 9.255
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.914
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.914
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022411 0 4 6 6 6 17 21 17 51 28 140 115
2022/2023497 58 29 19 17 57 53 3 57 71 92 32 9
2023/2024361 17 50 71 17 22 52 12 41 8 9 45 17
2024/20251.931 94 97 15 58 57 81 195 111 167 187 712 157
2025/20263.720 386 282 388 386 634 138 476 216 388 301 64 61
2026/202799 73 26 0 0 0 0 0 0 0 0 0 0
Totale 9.255